科倫博泰生物-B(06990.HK):核心產品蘆康沙妥珠單抗(sac-TMT)於2024年美國癌症研究協會年會上的研究成果
格隆匯4月8日丨科倫博泰生物-B(06990.HK)發佈公吿,公司將在於2024年4月5日至10日於美國加利福尼亞州聖地牙哥舉行的 2024年美國癌症研究協會(AACR)年會上,於當地時間2024年4月9日下午1:30至 5:00的壁報展示環節(摘要報吿編號:CT247)公佈其抗TROP2 ADC蘆康沙妥珠單抗(sac-TMT)(前稱SKB264/MK-2870)用於既往接受過治療的晚期非小細胞肺癌(NSCLC)患者的2期研究的最新療效和安全性結果,並於當地時間下午2:30至 4:30的口頭報吿環節(摘要報吿編號:CT038)以口頭報吿的形式公佈其抗TROP2 ADC蘆康沙妥珠單抗(sac-TMT)用於既往接受過治療的晚期胃癌或食管胃交界部 (GEJ)癌症患者的2期研究的初步療效和安全性結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.